Skip to content
etf.net

Launched · SEC filings

VanEck Biotech ETF

BBHNasdaqB

$235.92−3.30 (−1.38%)

At close: Oct 13, 2026, 4:00 PM

B67/ 100

Rank 5 of 17 in Biotech & Genomics

B67/100Rank 5 of 17inBiotech & Genomics
Intraday session: down, 79 prints from 239.22 to 235.92. Range 235.63 to 238.31. Use the arrow keys to read each point.237.00238.0010 AM12 PM2 PM4 PM
Expense ratio
0.35%
Fund size
$482M
1Y total return
+39.7%
Yield · Last 12 months
0.40%
Holdings
25
Avg volume · 30D
0M sh
NAV per share
$239.26
52W range
low $171.64high $246.55
Launched
Filings
SEC EDGAR

The ETF.net BBH Grade

Based on 5 of 6 pillars

B

Score 67 out of 100

Category
Biotech & Genomics⁠
Rank
5 of 17
Six-pillar profile for BBH. Scores out of 100: Cost 81, Risk 68, Mission not scored, Tradability 66, Holdings 28, Durability 69. Strongest: Cost (81). Weakest: Holdings (28). Based on 5 of 6 pillars.

Score 67 of 100 falls in the B band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.

  • Cost

    The fund’s net expense ratio, ranked against its category.
    A81 out of 100
    Rank 3 of 17

  • Mission

    Whether the fund did what it promised, tested against its stated mandate.
    Not scored

  • Risk

    How the fund held up when markets fell: downside volatility, drawdowns and tail loss.
    B68 out of 100
    Rank 5 of 17

  • Tradability

    How easy the fund is to trade: daily volume, and how far its price strays from net asset value.
    B66 out of 100
    Rank 5 of 17

  • Holdings

    How concentrated the fund is, and how complete and current its disclosed holdings are.
    D28 out of 100
    Rank 17 of 17

  • Durability

    Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.
    B69 out of 100
    Rank 6 of 17

Our read on BBH

ETF.net Research

BBiotech, distilled. BBH tracks an index of around 25 US-listed drug and diagnostics companies, so each name carries real weight instead of getting lost in a crowd. Running since 2011, at a fee below the typical biotech fund.

Stated mandate

The fund seeks to track, before fees and expenses, the price and yield performance of the MVIS US Listed Biotech 25 Index. That index represents companies involved in developing, producing, marketing, and selling drugs based on genetic analysis and diagnostic equipment.

Why people hold it

  1. 010.35% a year, below the 0.50% typical for biotech funds and level with XBI.
  2. 02Around 25 holdings, so the leaders in the index actually move the fund rather than getting diluted across hundreds of tickers.
  3. 03Rules-based: it follows the MVIS US Listed Biotech 25 Index, no manager guessing which drug pipeline pans out.vaneck.com
  4. 04Trading since 2011, through several full biotech cycles, and it sits in the upper half of its biotech peer group.

Worth knowing

  1. 01Concentration cuts both ways: with roughly 25 names, one failed trial or patent cliff lands hard.
  2. 02One of the less-traded funds in the biotech aisle, so bid-ask spreads deserve attention. Limit orders are the usual fix.
  3. 03Not the cheapest seat in the category: IBBQ charges 0.19%.

BBH Holdings

As of Oct 13, 2026
Asset class
Stocks
Holdings
25
Top-10 weight
73%
Largest holding
AMGN15.8%

Sectors

  • Health Care100.0%

Geography

  • United States88.86%
  • Netherlands5.52%
  • Switzerland2.81%
  • Germany1.58%
  • Ireland1.23%
The fund’s holdings, weight-ordered — page 1 of 2.
#TickerCompanyWeight %SharesMarket valueIn ETFs
001AMGNAmgen Inc15.79%184,506$77M491
002GILDGilead Sciences Inc13.59%435,801$66M492
003VRTXVertex Pharmaceuticals Inc8.15%77,463$40M422
004MRNAModerna Inc7.20%155,157$35M286
005REGNRegeneron Pharmaceuticals Inc6.51%42,244$32M411
006NTRANatera Inc5.27%63,701$26M238
007IQVIqvia Holdings Inc4.39%81,878$21M289
008ILMNIllumina Inc4.18%72,823$20M322
009ARGXArgenx Se4.01%23,582$19M70
010RVMDRevolution Medicines Inc3.97%101,314$19M176
011GHGuardant Health Inc2.87%83,072$14M175
012BIIBBiogen Inc2.77%59,559$13M324
013ONCBeone Medicines Ltd2.72%37,142$13M36
014ALNYAlnylam Pharmaceuticals Inc2.59%53,938$13M259
015UTHRUnited Therapeutics Corp2.31%20,376$11M266

Showing 1–15 of 25 holdings

BBH Performance

Launched Dec 20, 2011

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

BBH$13,971
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$12,044
Oct 10, 2025 to Oct 12, 2026. BBH $13,971. SPY $12,044. Use the arrow keys to read each point.$9,399$12,056$14,712Oct 2025Apr 2026Oct 2026

Oct 10, 2025 – Oct 12, 2026

Returns run to the Oct 12, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for BBH. Periods over one year show the average yearly return.
PeriodBBH
Year to date+26.4%
1 month+4.3%
3 months+16.4%
1 year+39.7%
3 yearsper year+15.9%
5 yearsper year+5.0%
10 yearsper year+8.8%

As of the close, with distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for BBH
YearReturn barBBH
2026 YTD+26.4%
2025+21.2%
2024−4.3%
2023+3.9%
2022−15.2%
2021+11.8%
2020+22.1%

BBH in the news

Filtered to BBH · Biotech & Genomics

BBH Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Oct 12, 2026.
0.40%Last 12 months
Payout per share
$0.96Last 12 months
Last payment
$0.96 per share
Paid on
Shares bought on or after this date do not qualify for this distribution.
Frequency
Annual

Distribution history

2017–2026

One bar per payment. 9 payments from 2017 to 2026 YTD. Dec 18, 2017 $0.68; Dec 20, 2018 $0.55; Dec 23, 2019 $0.47; Dec 21, 2020 $0.61; Dec 20, 2021 $0.40; Dec 19, 2022 $0.75; Dec 18, 2023 $0.71; Dec 23, 2024 $1.25; Dec 22, 2025 $0.96. Use the arrow keys to read each point.2017201820192020202120222023202420252026YTD
Ex-datePay dateAmount per share
Dec 22, 2025Dec 26, 2025$0.96
Dec 23, 2024Dec 24, 2024$1.25
Dec 18, 2023Dec 22, 2023$0.71
Dec 19, 2022Dec 23, 2022$0.75
Dec 20, 2021Dec 27, 2021$0.40
Dec 21, 2020Dec 28, 2020$0.61
Dec 23, 2019Dec 30, 2019$0.47
Dec 20, 2018Dec 27, 2018$0.55
Dec 18, 2017Dec 22, 2017$0.68
Dec 19, 2016Dec 23, 2016$0.33
Dec 21, 2015Dec 28, 2015$0.34
Dec 23, 2013Dec 30, 2013$0.003

BBH Risk

How much the fund’s monthly returns vary, scaled to a year.
17.8%
Annualised · 36 months to Sep 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
0.71
vs 3-month T-bills · to Sep 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−34.6%
Trough Jun 2022
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
0.58
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

BBH Cost

Expense ratio0.35%
  • The middle half of Biotech & Genomics funds
  • Median 0.47%

2 of the 17 Biotech & Genomics funds charge less.

BBH costs $35.00 a year on $10,000. The median Biotech & Genomics fund costs $47.00.

Other funds in Biotech & Genomics

See others